Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
News
EC approves Santen’s Ryjunea to slow progression of paediatric myopia
Therapy indicated for children aged 3 to 14 at treatment initiation
Linear Diagnostics awarded £1m to develop rapid STI test
New funding supports development of diagnostic platform
NICE recommends Sogroya for growth hormone deficiency in children
Treatment provides option for children with growth failure
PharmaTimes Clinical Researcher of the Year – The Americas
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
NICE recommends mirikizumab for Crohn’s disease treatment
New guidance expands treatment options for eligible patients
AstraZeneca’s Forxiga recommended for chronic kidney disease treatment
Updated guidance from NICE expands eligibility for dapagliflozin us
Lumanity and Parker Institute partner to support delivery of new immunotherapies
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share...
Eli Lilly acquires SiteOne Therapeutics to advance treatment for chronic pain
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid...
NICE recommends sparsentan for IgA nephropathy
First non-immunosuppressive dual-action therapy approved for eligible patients
Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology
Company secures regulatory approvals for commercial rollout in UK and US
MHRA Board meets in Scotland for first time, reinforcing UK-wide health priorities
The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time,...
Sonrai and AOA Dx partner to accelerate ovarian cancer test development
Strategic collaboration aims to improve early diagnosis
Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia
The drug was recently approved in the US for familial chylomicronaemia syndrome
